Pfizer Corporation (PFE) - Company Value to Net Income

Corporate emblem and logo of Pfizer Inc (PFE)

Pfizer Inc. (PFE) is currently undergoing a deep structural transformation following a decline in profits from COVID-related products. Despite this, the business remains a defensive asset with resilient demand for pharmaceuticals. The issuer's P/E dynamics confirm these fluctuations, where 41.30 represents the current level of the metric. Global scale and capital allow the behemoth to acquire biotech startups to solidify its leadership.

PFE pfizer.com: Price to Earnings Ratio in the range 07/04/2022 - 11/10/2026

Comprehensive metric breakdowns and analytics for Pfizer Corporation (PFE)

- share price and expert price forecast:
Price Performance Chart pfizer.com|PFE - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Pfizer Inc.|PFE - Total Company Value
- balance sheet net asset value indicators:
Net Asset Value per Share Pfizer|PFE - Company Book Value|Market Value to Book Value Ratio pfizer.com|PFE - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Ratio Pfizer Inc.|PFE - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Pfizer Corp|PFE - Company Debts|Debt to Book Value Ratio Pfizer Inc.|PFE - Company Long-Term Debts|Short-Term Indebtedness Pfizer|Critical Liquidity Ratio pfizer.com
- business earnings and investment ratios data:
PFE - Net Profit|Forward Earnings Pfizer Inc.|PFE - P/E Multiple|Market Cap to Projected Earnings Pfizer Inc|PFE - Price/Earnings to Growth Multiple|Company Value to Operating Income Before Depreciation Ratio Pfizer Inc.|PFE - Operating profit EBITDA|Net earnings per one share for the last twelve months Pfizer|PFE - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months pfizer.com|PFE - Net earnings per share growth this year|Expected earnings per share trend next year Pfizer Inc.
Comprehensive company analysis:pfizer.com PFE
Product sample of Pfizer Inc.

The global pharmaceutical ecosystem of Pfizer Inc. (PFE), with its protected patent portfolio and government contracts, requires a precise business valuation. The P/E ratio correlates the current share price with net income, determining the payback period for invested capital. This metric warns investors against overpaying for assets during periods of high volatility. The price action of the P/E multiple clearly illustrates the fairness of the company's market value.

Key competitors

LLY: Company Value to Net Income|P/E Multiple ABBV|AZN (AstraZeneca Plc) - Company Value to Net Income|Price to Earnings Ratio Novartis Inc. NVS|MSD (MRK) - Market Cap to Earnings|NVO - Price to Earnings Ratio|AMGN: Price to Earnings Ratio|SNY: P/E Multiple|Price to Earnings Multiple BMY|GSK (GlaxoSmithKline plc) - P/E Multiple|Takeda Pharma (TAK) - Business Payback Period|Price to Earnings Ratio Teva (TEVA)|drreddys.com - Price to Earnings Multiple|P/E Multiple VTRS (Viatris)|Market Cap to Net Income Ratio Roivant|ZLAB - Price to Earnings Ratio|Market Cap to Net Income BHC|COSM: P/E Multiple